---
$id: https://graph.org.ai/products/commodity/51111761
$type: Product
source: UNSPSC
code: "51111761"
title: "Ranibizumab"
class: "51111700"
classTitle: "Antineoplastic antibiotics"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Ranibizumab

**UNSPSC Code**: 51111761
**Class**: [Antineoplastic antibiotics](Antineoplastic antibiotics.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an immunoconjugate with the molecular formula C2158H3282N562O681S12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZL1R02VT79, more generally known as ranibizumab. European Medicines Agency schedules ranibizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22314. The term RANIBIZUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 18, no. 3, 2004, list 52. Most nations schedule ranibizumab under HS 30021091 and SITC 54163. As of Q4 2014, RANIBIZUMAB remains the US FDA Preferred Term for this commodity. Ranibizumab bears US NLM identifiers UMLS ID C1566537 and NCI Concept Code C67562. SMILES: none.

